Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells

References

• Gryziak M, Woźniak K, Kraj L, et al. Milestones in the treatment of hepatocellular carcinoma: a systematic review. Crit Rev Oncol Hematol. 2021;157:103179.
   PubMed Web of Science ®Google Scholar
• Schipilliti FM, Garajová I, Rovesti G, et al. The growing skyline of advanced hepatocellular carcinoma treatment: a review. Pharmaceuticals (Basel). 2021;14(1):43.
   PubMedGoogle Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Atsukawa M, et al. Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma. Oncology. 2019;97(5):277–285.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296.
   PubMed Web of Science ®Google Scholar
• Feins S, Kong W, Williams EF, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–s9.
   PubMed Web of Science ®Google Scholar
• Subklewe M, von Bergwelt-Baildon M, Humpe A. Chimeric antigen receptor T cells: a race to revolutionize cancer therapy. Transfus Med Hemother. 2019;46(1):15–24.
   PubMed Web of Science ®Google Scholar
• Song MK, Park BB, Uhm JE. Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic malignancies. Int J Mol Sci. 2019;20(20):5010.
   PubMed Web of Science ®Google Scholar
• Delfau-Larue MH, de Leval L, Joly B, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97(10):1594–1602.
   PubMed Web of Science ®Google Scholar
• Wang YL, Zhu ZJ, Teng DH, et al. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol. 2012;18(19):2408–2414.
   PubMed Web of Science ®Google Scholar
• Li B, Liu H, Shang HW, et al. Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. Afr Health Sci. 2013;13:703–709.
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Chanmee T, Komtong S, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol. 2010;25(1):129–137.
   PubMed Web of Science ®Google Scholar
• Jakubovic BD, Jothy S. Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol. 2007;82(2):184–189.
   PubMed Web of Science ®Google Scholar
• Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014;20(24):6418–6428.
   PubMed Web of Science ®Google Scholar
• Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002;20(1):70–75.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Gold PJ, El-Khoueiry AB, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013;19(4):920–928.
   PubMed Web of Science ®Google Scholar
• Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014;588(2):377–382.
   PubMed Web of Science ®Google Scholar
• Zah E, Lin MY, Silva-Benedict A, et al. ADDENDUM: T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4(7):639–641.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011;11(7):855–873.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Wylie T, Germino E, et al. Next-generation sequencing identifies the natural killer cell microRNA transcriptome. Genome Res. 2010;20(11):1590–1604.
   PubMed Web of Science ®Google Scholar
• Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036–3052.
   PubMed Web of Science ®Google Scholar
• Dees S, Ganesan R, Singh S, et al. Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer. Mol Cancer Ther. 2020;19(12):2409–2421.
   PubMed Web of Science ®Google Scholar
• Shi H, Sun M, Liu L, et al. Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Mol Cancer. 2014;13(1):219.
   PubMedGoogle Scholar
• DeRenzo C, Gottschalk S. Genetically modified T-cell therapy for osteosarcoma. Adv Exp Med Biol. 2014;804:323–340.
   PubMed Web of Science ®Google Scholar
• Durinck K, Wallaert A, Van de Walle I, et al. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia. Haematologica. 2014;99(12):1808–1816.
   PubMed Web of Science ®Google Scholar
• Cleary KLS, Chan HTC, James S, et al. Antibody distance from the cell membrane regulates antibody effector mechanisms. J Immunol. 2017;198(10):3999–4011.
   PubMed Web of Science ®Google Scholar
• Hudecek M, Sommermeyer D, Kosasih PL, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125–135.
   PubMed Web of Science ®Google Scholar
• Wei HP, Yang N, Gu ZY, et al. [Application of chimeric antigen receptor-modified nk cells in multiple Myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018;26:796–801.
   PubMedGoogle Scholar
• Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520–531.
   PubMed Web of Science ®Google Scholar